Skip to content
  • Report Harm
  • Newsletter
  • Press Room
Facebook Linkedin YouTube Instagram Twitter Spotify
Benzodiazepine Information Coalition
  • About BenzodiazepinesExpand
    • Benzo BasicsExpand
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • PrescribingExpand
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing RisksExpand
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • DeprescribingExpand
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing RisksExpand
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special PopulationsExpand
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About UsExpand
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • VolunteerExpand
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our ImpactExpand
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • ResourcesExpand
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Donate
Facebook Linkedin Twitter Instagram YouTube
Benzodiazepine Information Coalition

Class Actions and Lawsuits—and Reporting Harm 

Table of Contents
  • Class Actions in the United Kingdom
  • Class Actions in the United States
  • Medical Malpractice Lawsuits
  • Filing a Medical Board Complaint
  • Reporting Harm to the FDA

Class Actions in the United Kingdom

Image by Okan Caliskan from Pixabay

In the 1980s and 1990s, benzodiazepines were the subject of the largest-ever class-action lawsuit against drug manufacturers in the United Kingdom. This lawsuit involved 14,000 patients, 1,800 law firms, and over £50 million spent on legal aid and by the drug companies. The suit alleged that the drug manufacturers were aware of the potential of benzodiazepines to cause physical dependence, but intentionally withheld this information from doctors and other medical prescribers.

Patients simultaneously sued 117 general practitioners and 50 health authorities in an attempt to recover damages for suffering and loss caused by the harmful effects of benzodiazepine dependence and withdrawal syndromes.

Unfortunately, the suit never reached a settlement or verdict. While the United Kingdom provides government funding for legal assistance to those who cannot afford to pay a lawyer, the funding for this suit was withdrawn in 1993-1994. In addition, there were many allegations that the pharmaceutical company’s consulting psychiatrists and expert witnesses had conflicts of interest.

What was notable about this suit is that it led some prescribers to require that patients sign an informed consent form before being prescribed benzodiazepines, and to recommend that all patients be warned, prior to the initiation of benzodiazepine drug “treatment,” of the potential for this class of drug to cause dependence and withdrawal issues. On the other hand, actual changes in British law that resulted from this landmark trial would end up making future class action lawsuits more difficult.

Following the collapse of the litigation, the benzodiazepine harm problem became even more insidious. In just three years, between 1994 and 1997, the number of prescriptions for sedatives / hypnotics increased, with prescriptions for Valium alone escalating by 15 percent. In addition, by 1999, prescriptions for the new sedative / hypnotic drugs—Z-drugs such as Zolpidem (Ambien) and Zopiclone (Zimovane / Imovane)—climbed to about 2 million per year, even though the number of adverse events associated with these drugs was much greater (x 100) than for any of the benzodiazepines.

Class Actions in the United States

There have been no American class action lawsuits related to benzodiazepines. Most benzodiazepines prescribed today are generics, and according to a 2011 Supreme Court decision, generic manufacturers cannot be sued for failure to warn. The Court’s reasoning was that the FDA requires generic and brand-name manufacturers to use the same warning label, which can only be updated by the brand-name manufacturer, making it unfair to hold the generic manufacturer responsible for something it could not legally address.

The Supreme Court decision failed to set a precedent as to what harmed patients could or should do instead. While it would be intuitive in such cases to file a lawsuit against the patent holder—usually the brand-name manufacturer—not every state allows such an action. Some states have decided that if a patient has never taken the brand-name equivalent of a drug, the brand-name manufacturer should not be held responsible for any harm. This leaves many patients in a situation where there is no recourse for filing suit in the case of legitimate harm.

Medical Malpractice Lawsuits

When it comes to individual patients or their families who have been harmed by benzodiazepines, there has been some successful litigation and monetary compensation. Whereas sixty years of appeals to ethics, evidence, guideline recommendations, and accounts of devastating harm and loss have seemed to fall on closed ears, legal action has in some cases been an important way to address the benzodiazepine crisis.

In the United States it may be difficult to find an attorney knowledgeable enough about benzodiazepine harm to successfully file and win a lawsuit. In addition, the payouts, like all medical malpractice payouts, may be capped at a very low amount, depending on state rules. Additionally there are statutes of limitations in effect that require initiating a suit within a certain amount of time. Benzodiazepine Information Coalition has compiled a list of benzodiazepine aware attorneys, but the list is very short, and the attorneys are quite selective in choosing cases.

Despite these restrictions, many patients in both the United States and abroad whose situations fit the necessary criteria and who are able to meet the legal deadlines have been successful in suing their prescribers for benzodiazepine-induced harm. Most of these lawsuits result in settlements—meaning they do not go to trial—and often the terms of the settlement are confidential. A public U.K. settlement in 2015 is that of Luke Montagu, founder of the Council for Evidence-based Psychiatry (CEPUK). In the United States, in 2023, Kathi Donald, a pediatric intensive care nurse, settled with her medical provider for her prescribed benzodiazepine injury, leaving her unable to work. Dr. Josef Witt-Doerring, who serves on our board, was an expert witness in her case. He interviewed both her and her attorney about this case in the video below.

Dr. Josef Witt-Doerring interviews Kathi Donald about her successful benzodiazepine litigation
Dr. Josef Witt-Doerring interviews malpractice attorney Hoyt Hart

In the past, Massachussets benzodiazepine advocate Geraldine Burns successfully sued her physician for benzodiazepine harm. She interviewed her attorney, Mike Mosher, in this video below.

Geraldine Burns interviews Mike Mosher

Filing a Medical Board Complaint

In the hope of preventing future harm to others, and in an attempt to force benzodiazepine education on the prescriber that harmed them, some patients take a medical complaint route. Filing a complaint about negligent medical providers with your State Medical Board (or another prescriber regulatory agency, depending on where you live) may be an appropriate way to bring to your doctor’s attention the harm you have experienced from benzodiazepine prescribing or irresponsible cessation. Doctors prefer to avoid formal complaints, so such a complaint could be a significant motivator.

On the other hand, legal and regulatory approaches come with their own problems, as they often don’t encourage learning, but instead teach avoidance behaviors. Lawyers knowledgeable about benzodiazepine harm are rare, and state medical boards typically do not understand the full nature of the harm. Even if such actions are successful, they can potentially harm other patients, as doctors who fail to understand why the actions were taken against them may learn  only not to prescribe benzodiazepines, and they may stop prescriptions abruptly. Existing patients would then be forced to find a new prescriber or face a potentially deadly and disabling cessation.

Reporting Harm to the FDA

Beyond lawsuits and medical boards, one important place to anonymously report all harm without any risk to the patient or provider is the FDA. Benzodiazepine Information Coalition, along with other patient organizations such as Benzo Buddies, have joined together to participate in the FDA reporting program Medwatch. To learn more and report your own harm from benzodiazepines, click here.

Contact Us

Inquiries
bic@benzoinfo.com

As an awareness organization, we do not offer any support services or guidance. See our resources for services and support.

Mailing Address
1042 Ft. Union Blvd, PMB 1030
Midvale, Utah 84047

Support BIC

We were formed to change the lack of knowledge in the public and the medical system. But we cannot do it alone. We rely solely on donations to operate. We are a 501(c)(3) tax exempt organization.

DONATE

Newsletter

Get notified about the latest studies, updates, calls to action, media stories, and other information.

*

IMPORTANT: After signing up, check your email to confirm we have the correct address. If you do not see an email, check your spam. We will add you to our newsletter once you complete this step to ensure delivery.

Notices

Benzodiazepine Information Coalition is a 501(c)3 tax exempt organization.

EIN: 81-3442343

Privacy Policy
Medical Disclaimer
Terms and Conditions
Free Charity Hosting by Kualo

Facebook Linkedin YouTube Instagram Twitter Spotify

© 2023 Benzodiazepine Information Coalition

Scroll to top
  • About Benzodiazepines
    • Benzo Basics
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • Prescribing
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing Risks
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • Deprescribing
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing Risks
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special Populations
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About Us
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • Volunteer
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our Impact
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • Resources
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Search
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset